Lixte Biotechnology (NASDAQ:NMAD) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Lixte Biotechnology (NASDAQ:NMAD) from a hold rating to a sell rating in a report issued on Saturday morning.

Separately, Weiss Ratings cut Lixte Biotechnology from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Lixte Biotechnology Price Performance

Shares of NMAD stock opened at $4.15 on Friday. Lixte Biotechnology has a 12-month low of $2.36 and a 12-month high of $8.38. The firm has a market capitalization of $66.82 million, a price-to-earnings ratio of -4.15 and a beta of 1.29. The business has a 50 day simple moving average of $7.05 and a 200 day simple moving average of $5.07.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Axxcess Wealth Management LLC acquired a new stake in Lixte Biotechnology in the fourth quarter worth approximately $54,000. XTX Topco Ltd bought a new stake in shares of Lixte Biotechnology in the 4th quarter worth $57,000. Equitable Holdings Inc. bought a new stake in shares of Lixte Biotechnology in the 2nd quarter worth $74,000. Geode Capital Management LLC raised its stake in shares of Lixte Biotechnology by 25.9% in the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after buying an additional 10,722 shares in the last quarter. Finally, DRW Securities LLC lifted its holdings in shares of Lixte Biotechnology by 11.6% in the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after buying an additional 5,645 shares during the period. Institutional investors and hedge funds own 5.10% of the company’s stock.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.